These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36681041)

  • 1. The potential of vortioxetine in treating obsessive-compulsive disorder.
    Biswas T
    Asian J Psychiatr; 2023 Apr; 82():103460. PubMed ID: 36681041
    [No Abstract]   [Full Text] [Related]  

  • 2. Vortioxetine and Aripiprazole Combination in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Report.
    De Berardis D; Olivieri L; Nappi F; Rapini G; Vellante F; Matarazzo I; Serroni N; Di Giannantonio M
    J Clin Psychopharmacol; 2017 Dec; 37(6):732-734. PubMed ID: 29040153
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder.
    Pizarro M; Fontenelle LF; Paravidino DC; Yücel M; Miguel EC; de Menezes GB
    Expert Opin Pharmacother; 2014 Jul; 15(10):1391-401. PubMed ID: 24766145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Drug Ther Bull; 1995 Jun; 33(6):47-8. PubMed ID: 7587998
    [No Abstract]   [Full Text] [Related]  

  • 8. Tourette syndrome. Medical and surgical treatment of obsessive-compulsive disorder.
    Rapoport JL; Inoff-Germain G
    Neurol Clin; 1997 May; 15(2):421-8. PubMed ID: 9115472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and potential pharmacological treatments for obsessive-compulsive disorder.
    Davidson J; Bjorgvinsson T
    Expert Opin Investig Drugs; 2003 Jun; 12(6):993-1001. PubMed ID: 12783603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors.
    Vythilingum B; Cartwright C; Hollander E
    Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S7-13. PubMed ID: 11110014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder.
    Corregiari FM; Bernik M; Cordeiro Q; Vallada H
    Clinics (Sao Paulo); 2012; 67(4):335-40. PubMed ID: 22522758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathogenesis and treatment of obsessive-compulsive disorder.
    Dolberg OT; Iancu I; Sasson Y; Zohar J
    Clin Neuropharmacol; 1996 Apr; 19(2):129-47. PubMed ID: 8777767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder.
    Kayser RR
    J Clin Psychiatry; 2020 Sep; 81(5):. PubMed ID: 32926602
    [No Abstract]   [Full Text] [Related]  

  • 16. Treating obsessive-compulsive disorder.
    Long K; Long R
    Nurse Pract Forum; 1995 Sep; 6(3):136-7. PubMed ID: 7549614
    [No Abstract]   [Full Text] [Related]  

  • 17. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.
    Dell'Osso B; Allen A; Hollander E
    Expert Opin Pharmacother; 2005 Dec; 6(15):2727-40. PubMed ID: 16316311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond depression: citalopram for obsessive-compulsive disorder.
    Pato MT
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S19-26. PubMed ID: 10471169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venlafaxine treatment of obsessive-compulsive disorder: case reports.
    Marazziti D
    CNS Spectr; 2003 Jun; 8(6):421-2. PubMed ID: 12858131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of treatment response in pediatric obsessive-compulsive disorder.
    Grados MA; Ginsburg GS; Drake KL; Kingery JN
    J Am Acad Child Adolesc Psychiatry; 2009 May; 48(5):573-574. PubMed ID: 19395904
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.